CN Patent

CN104069117A — 安普那韦在制备预防或治疗缺血性心脑血管疾病的药物中的应用

Assigned to Binzhou Medical College · Expires 2014-10-01 · 12y expired

What this patent protects

本发明涉及一种药物新用途，具体地涉及安普那韦通过抑制HMGB1的表达预防或治疗缺血性心脑血管疾病。在上述应用中，其使用剂量范围是120mg～6000mg；优选240～3000mg。

USPTO Abstract

本发明涉及一种药物新用途，具体地涉及安普那韦通过抑制HMGB1的表达预防或治疗缺血性心脑血管疾病。在上述应用中，其使用剂量范围是120mg～6000mg；优选240～3000mg。

Drugs covered by this patent

Patent Metadata

Patent number
CN104069117A
Jurisdiction
CN
Classification
—
Expires
2014-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Binzhou Medical College
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.